Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Sacituzumab Govitecan, A Kind of ADC Drug Against Triple-Negative Breast CancerBy: Biochempeg Scientific Inc. Sacituzumab govitecan is the first antibody-drug conjugate approved by the FDA specifically for relapsed or refractory metastatic triple-negative metastatic breast cancer. It is also the first FDA-approved anti–Trop- Metastatic triple-negative breast cancer is an aggressive form of breast cancer with limited treatment options. Chemotherapy has been the mainstay of treatment for triple-negative breast cancer. The approval of sacituzumab govitecan represents a new targeted therapy for patients living with this aggressive malignancy. IMMU-132-01 The FDA approved sacituzumab govitecan based on the results of the phase II IMMU-132-01 clinical trial of 108 patients with metastatic triple-negative breast cancer who had received a range of 2 to 10 prior treatments for metastatic disease. Patients received sacituzumab govitecan at 10 mg/kg intravenously on days 1 and 8 every 21 days. Tumor imaging was obtained every 8 weeks, and patients were treated until disease progression or intolerance to therapy. The efficacy of sacituzumab govitecan was based on the overall response rate. The overall response rate was 33.3% (95% confidence interval [CI] = 24.6%–43.1%) Continued approval of sacituzumab govitecan may be contingent upon verification of clinical benefit in the confirmatory phase III ASCENT study, which was recently halted by the independent data safety monitoring committee for compelling evidence of efficacy across multiple endpoints. The recommended sacituzumab govitecan dose is 10 mg/kg administered by intravenous infusion administered on days 1 and 8 every 21 days until disease progression or unacceptable toxicity. Biochempeg, a leading PEG supplier can provide GMP standard PEG derivatives and ADC linkers with small quantity or bulk orders to customers all over the world based on their special quality requirements. It provides 2-((Azido-PEG8- Company: Biochempeg Scientific Inc. Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA Email: sales@biochempeg.com Website: https://www.biochempeg.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|